menu
    • menu
    [{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cystic Fibrosis Foundation \/ Royalty Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Cystic Fibrosis Foundation

    Menu

    Cystic Fibrosis Foundation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNSP003

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Synspira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement

                            Details : Synspira Therapeutics signed this agreement to support the development of SNSP003, Synspira’s orally delivered enzyme replacement therapy to treat Malabsorption Syndrome.

                            Product Name : SNSP003

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            December 02, 2020

                            Lead Product(s) : SNSP003

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Synspira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivacaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Royalty Pharma

                            Deal Size : $650.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Royalty Pharma Acquires Additional Royalty Interest from the Cystic Fibrosis Foundation

                            Details : Funding will support the CF Foundation’s work to fund research and drug development and advance high-quality, specialized CF care. KALYDECO® (ivacaftor) as First and Only CFTR Modulator, indicate to treat Eligible Infants With CF as Early as Four Mont...

                            Product Name : Kalydeco

                            Product Type : Other Small Molecule

                            Upfront Cash : $575.0 million

                            February 11, 2020

                            Lead Product(s) : Ivacaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Royalty Pharma

                            Deal Size : $650.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth